Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: MCL1

Summary for MCL1

Gene information	Gene symbol	MCL1
	Ensembl ID	ENSG00000143384
	Entrez ID	4170
	Gene name	MCL1 apoptosis regulator, BCL2 family member
	Synonyms	BCL2L3\|Mcl-1
	Gene type	protein_coding
	UniProtAcc	Q07820

Top

Dataset with differentially expressed gene: MCL1

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	-0.298215	1.52e-35
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.34789	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.36918	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	0.88254	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	cDCs	0.830735	3.04e-30
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	0.417455	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.305052	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	-0.294743	3.78e-37
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD4+ T cells	-0.536684	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.254664	4.53e-03
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.332722	1.39e-40
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.256244	1.08e-16
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	-0.344759	1.56e-15
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	cDCs	-0.438933	2.43e-04
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	0.439194	5.54e-16
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD8+ T cells	0.450438	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	0.387925	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	0.391054	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	-0.273915	4.73e-14
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	0.372826	0.00e+00
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Mono/Macro	-0.856601	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-1.0604	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-1.25876	0.00e+00
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	post	cDCs	0.283807	9.25e-06
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	pre	Mono/Macro	0.305824	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.524813	6.79e-23
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.550088	3.14e-28
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	Mono/Macro	0.341791	4.59e-34
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	pDCs	1.33949	8.61e-05
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.684825	8.71e-18
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	B cells	0.268338	1.46e-06
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.584992	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Mono/Macro	0.308192	9.92e-14
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	-0.726493	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Mono/Macro	0.293598	6.96e-09
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	0.877975	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	Malignant cells	-0.347219	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	Malignant cells	-0.338046	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	-1.58954	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	-0.258971	8.17e-20
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	0.255162	1.93e-04
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	0.265053	2.60e-08
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	0.593031	3.76e-41
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	-0.450202	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	0.978651	0.00e+00
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	-0.337932	4.81e-23
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	-0.271276	0.00e+00

Top

Expression of MCL1 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to MCL1

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Gene symbol	Mechanism
MCL1	Unusual Activation of Pro-survival Pathway

Page: 1

Top

MicroRNAs (miRNA) regulating MCL1

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
MCL1	hsa-miR-3686	99.3803	NM_001197320
MCL1	hsa-miR-548x-3p	97.4957	NM_001197320
MCL1	hsa-miR-548aj-3p	97.4957	NM_001197320
MCL1	hsa-miR-548j-3p	97.0379	NM_001197320
MCL1	hsa-miR-548ah-3p	97.0379	NM_001197320
MCL1	hsa-miR-548aq-3p	97.0379	NM_001197320
MCL1	hsa-miR-548ae-3p	97.0379	NM_001197320
MCL1	hsa-miR-548am-3p	97.0379	NM_001197320
MCL1	hsa-miR-1297	91.9763	NM_001197320
MCL1	hsa-miR-4465	90.2608	NM_001197320
MCL1	hsa-miR-26b-5p	90.2608	NM_001197320
MCL1	hsa-miR-26a-5p	90.2608	NM_001197320
MCL1	hsa-miR-520f-3p	89.7947	NM_001197320
MCL1	hsa-miR-106b-5p	88.7851	NM_001197320
MCL1	hsa-miR-20a-5p	88.7851	NM_001197320
MCL1	hsa-miR-5682	88.4834	NM_001197320
MCL1	hsa-miR-4666a-3p	87.8721	NM_182763
MCL1	hsa-miR-5583-5p	87.7428	NM_001197320
MCL1	hsa-miR-3129-3p	87.7428	NM_001197320
MCL1	hsa-miR-103a-2-5p	86.9467	NM_182763
MCL1	hsa-miR-103a-1-5p	86.9467	NM_182763
MCL1	hsa-miR-302e	86.5057	NM_001197320
MCL1	hsa-miR-876-3p	86.4507	NM_182763
MCL1	hsa-miR-29c-3p	86.3781	NM_001197320
MCL1	hsa-miR-29a-3p	86.3781	NM_001197320
MCL1	hsa-miR-29b-3p	86.3781	NM_001197320
MCL1	hsa-miR-106a-5p	85.5679	NM_001197320
MCL1	hsa-miR-519d-3p	85.5679	NM_001197320
MCL1	hsa-miR-526b-3p	85.5679	NM_001197320
MCL1	hsa-miR-93-5p	85.5679	NM_001197320
MCL1	hsa-miR-17-5p	85.5679	NM_001197320
MCL1	hsa-miR-20b-5p	85.5679	NM_001197320
MCL1	hsa-miR-4319	85.0798	NM_001197320
MCL1	hsa-miR-1289	84.9287	NM_182763
MCL1	hsa-miR-5697	83.8559	NM_001197320
MCL1	hsa-miR-302b-3p	83.3899	NM_001197320
MCL1	hsa-miR-520e-3p	83.3899	NM_001197320
MCL1	hsa-miR-373-3p	83.3899	NM_001197320
MCL1	hsa-miR-520a-3p	83.3899	NM_001197320
MCL1	hsa-miR-520d-3p	83.3899	NM_001197320
MCL1	hsa-miR-302a-3p	83.3899	NM_001197320
MCL1	hsa-miR-520c-3p	83.3899	NM_001197320
MCL1	hsa-miR-302c-3p	83.3899	NM_001197320
MCL1	hsa-miR-302d-3p	83.3899	NM_001197320
MCL1	hsa-miR-520b-3p	83.3899	NM_001197320
MCL1	hsa-miR-372-3p	83.3899	NM_001197320
MCL1	hsa-miR-92a-3p	82.9854	NM_021960
MCL1	hsa-miR-92b-3p	82.9854	NM_021960
MCL1	hsa-miR-32-5p	82.9854	NM_021960
MCL1	hsa-miR-320c	82.8472	NM_182763

Page: 1 2

Top

Motifs and transcription factors (TFs) regulating MCL1

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
MCL1	kznf__ZNF45_Imbeault2017_OM_RCADE	ZNF45 (directAnnotation).
MCL1	metacluster_84.18	RARA (directAnnotation).
MCL1	hdpi__NFATC3	NFATC3 (directAnnotation).
MCL1	transfac_pro__M06550	ZNF519 (directAnnotation).
MCL1	c2h2_zfs__M0385	MTF1 (inferredBy_Orthology).
MCL1	metacluster_103.2	ZNF136; ZNF680 (directAnnotation).
MCL1	dbtfbs__ZNF610_HEK293_ENCSR691TXI_merged_N1	ZNF610 (directAnnotation).
MCL1	jaspar__MA1633.2	BACH1 (directAnnotation).
MCL1	taipale_tf_pairs__GCM1_CEBPB_ATRSGGGNNNNTTRCGYAAN_CAP_repr	CEBPB; GCM1 (directAnnotation).
MCL1	hdpi__ZNF695	ZNF695 (directAnnotation).
MCL1	kznf__ZNF100_Imbeault2017_RP_RCADE	ZNF100 (directAnnotation).
MCL1	metacluster_119.1	ZNF677 (directAnnotation).
MCL1	kznf__ZNF343_Imbeault2017_OM_RCADE	ZNF343 (directAnnotation).
MCL1	metacluster_50.1	BATF; BATF; BATF; BATF; BNC2; FOS; FOSB; FOSL1; FOSL1; IRF4; JUN; JUN; JUNB; JUNB; JUNB; JUNB; JUND; JUND; JUND; JUND; JUND; SMAD2; SMAD3 (directAnnotation). BATF; BATF; BATF; FOS; FOSL1; FOSL2; JDP2; JUN; JUN; JUND (inferredBy_Orthology).
MCL1	tfdimers__MD00209	MZF1; TBP (directAnnotation).
MCL1	metacluster_27.9	ZSCAN31 (directAnnotation).
MCL1	jaspar__MA1938.1	NHLH1 (directAnnotation).
MCL1	tfdimers__MD00217	LTF; MZF1 (directAnnotation).
MCL1	transfac_pro__M06104	ZNF16 (directAnnotation).
MCL1	hdpi__SCAND2	SCAND2P (directAnnotation).
MCL1	taipale_tf_pairs__MGA_DLX2_SYAATTANWGGTGYGA_CAP	DLX2; MGA (directAnnotation).
MCL1	hdpi__MAGED4	MAGED4 (directAnnotation).
MCL1	transfac_pro__M05423	RREB1 (directAnnotation).
MCL1	transfac_pro__M06577	ZNF594 (directAnnotation).
MCL1	transfac_pro__M05379	ZNF740 (inferredBy_Orthology).
MCL1	metacluster_72.2	ZNF16; ZNF16 (directAnnotation).
MCL1	tfdimers__MD00215	LEF1; STAT1 (directAnnotation).
MCL1	transfac_pro__M06671	ZNF285 (directAnnotation).
MCL1	swissregulon__hs__GMEB2	GMEB2 (directAnnotation).
MCL1	transfac_pro__M02027	PARP1 (directAnnotation).
MCL1	metacluster_150.4	SKOR1; SKOR1; SKOR2; SKOR2 (directAnnotation).
MCL1	tfdimers__MD00386	GTF2IRD1; POU5F1 (directAnnotation).
MCL1	tfdimers__MD00207	HOXA13; PDX1 (directAnnotation).
MCL1	transfac_pro__M06795	ZNF780B (directAnnotation).
MCL1	metacluster_78.15	PAX7 (directAnnotation).
MCL1	tfdimers__MD00048	CDX2; IKZF1 (directAnnotation).
MCL1	tfdimers__MD00258	KLF4; POU2F1 (directAnnotation).
MCL1	metacluster_9.24	ALX1 (directAnnotation).
MCL1	transfac_pro__M06894	ZFP90 (inferredBy_Orthology).
MCL1	metacluster_9.30	POU3F2 (directAnnotation).
MCL1	transfac_pro__M05646	ZNF879 (directAnnotation).
MCL1	tfdimers__MD00097	GABPA; PAX4 (directAnnotation).
MCL1	hocomoco__NKX61_HUMAN.H11MO.1.B	NKX6-1 (directAnnotation).
MCL1	transfac_pro__M01234	PDX1 (directAnnotation).
MCL1	tfdimers__MD00421	ELF3; POU5F1 (directAnnotation).
MCL1	transfac_pro__M06860	ZNF549 (directAnnotation).
MCL1	jaspar__MA0863.1	MTF1 (directAnnotation).
MCL1	metacluster_7.7	SP2 (directAnnotation). KLF16 (inferredBy_Orthology).
MCL1	transfac_pro__M06849	ZNF528 (directAnnotation).
MCL1	tfdimers__MD00014	ARID3A; KLF4 (directAnnotation).

Page: 1 2 3

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."